These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29745884)

  • 1. Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis.
    Gudmann NS; Junker P; Juhl P; Thudium CS; Siebuhr AS; Byrjalsen I; Karsdal MA; Bay-Jensen AC
    Clin Exp Rheumatol; 2018; 36(5):829-835. PubMed ID: 29745884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study.
    Drobinski PJ; Bay-Jensen AC; Karsdal MA; Sardar S; Siebuhr AS
    Arthritis Res Ther; 2021 Jan; 23(1):13. PubMed ID: 33413588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
    Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
    Ann Rheum Dis; 2017 Jul; 76(7):1279-1284. PubMed ID: 28389552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased remodelling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: serological evaluation of a one-year prospective study of 149 Japanese patients.
    Gudmann NS; Hirata S; Karsdal MA; Kubo S; Bay-Jensen AC; Tanaka Y
    Clin Exp Rheumatol; 2018; 36(3):462-470. PubMed ID: 29465351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.
    Fleischmann RM; Halland AM; Brzosko M; Burgos-Vargas R; Mela C; Vernon E; Kremer JM
    J Rheumatol; 2013 Feb; 40(2):113-26. PubMed ID: 23322466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
    Garnero P; Thompson E; Woodworth T; Smolen JS
    Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial.
    Kremer JM; Blanco R; Halland AM; Brzosko M; Burgos-Vargas R; Mela CM; Rowell L; Fleischmann RM
    Clin Exp Rheumatol; 2016; 34(4):625-33. PubMed ID: 27087059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab.
    Tuckwell K; Gabay C; Sornasse T; Laubender RP; Wang J; Townsend MJ
    Adv Rheumatol; 2019 Dec; 59(1):54. PubMed ID: 31801637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
    Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction.
    Smolen JS; Avila JC; Aletaha D
    Ann Rheum Dis; 2012 May; 71(5):687-93. PubMed ID: 22121130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
    Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
    Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Tocilizumab Monotherapy Versus Tocilizumab and Methotrexate Combination Therapy in the Prevention of Radiographic Progression in Rheumatoid Arthritis: An Analysis Using Individual Patient Data From Multiple Clinical Trials.
    Verhoeven MMA; Tekstra J; Jacobs JWG; Bijlsma JWJ; van Laar JM; Pethö-Schramm A; Borm MEA; Lafeber FPJ; Welsing PMJ
    Arthritis Care Res (Hoboken); 2022 Jun; 74(6):889-895. PubMed ID: 33253497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of active, but not total MMP-3, is associated with treatment response in a phase III clinical study of rheumatoid arthritis.
    Siebuhr AS; Kjelgaard-Petersen CF; Sun S; Byrjalsen I; Christiansen C; Karsdal MA; Bay-Jensen AC
    Clin Exp Rheumatol; 2018; 36(1):94-101. PubMed ID: 28850021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
    Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
    J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522).
    Karsdal MA; Schett G; Emery P; Harari O; Byrjalsen I; Kenwright A; Bay-Jensen AC; Platt A
    Semin Arthritis Rheum; 2012 Oct; 42(2):131-9. PubMed ID: 22397953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serological identification of fast progressors of structural damage with rheumatoid arthritis.
    Siebuhr AS; Bay-Jensen AC; Leeming DJ; Plat A; Byrjalsen I; Christiansen C; van de Heijde D; Karsdal MA
    Arthritis Res Ther; 2013 Aug; 15(4):R86. PubMed ID: 23945134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
    Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Sep; 24(5):715-24. PubMed ID: 24313916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study.
    Pablos JL; Navarro F; Blanco FJ; Román-Ivorra JA; Alonso A; Martín Mola E; Cantalejo M; Ercole L; Rivero N;
    Clin Exp Rheumatol; 2019; 37(3):437-444. PubMed ID: 30299241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.